Bladder Cancer Trials

Benefits of clinical trials research - bladder cancer

This large-scale, randomised trial will determine the effects of adding mitomycin to BCG on cure rates, survival, side effects, and quality of life.

This study looks at whether Nab-Paclitaxel improves survival and is less toxic with improved quality of life compared with Paclitaxel.

This trial is aimed at managing bladder cancer that has spread into the wall of the bladder with the addition of pembrolizumab to the standard therapy of chemotherapy and radiation therapy.

This project follows on from Phase I, which involved qualitative research to develop a draft Non-Muscle Invasive Bladder Cancer Symptom Index (NMIBC-SI). The aim of the current project is to evaluate the psychometric properties of the NMIBC-SI. 

© ANZUP 2021. All rights reserved.